Scott Requadt

Filings by Scott Requadt span 2 companies, the busiest being Talaris Therapeutics, Inc. and ESSA Pharma Inc. We count 9 filings; the first trade dates from 31 December 2021 and the latest from 9 October 2025.

The open-market record is one-sided, with 3 purchases worth €222k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 4 share grants.

The median purchase comes to €35k. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 15 October 2025 came the latest disclosure, a transaction in ESSA Pharma Inc. The last insider purchase was made public on 2 August 2022, 1,538 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.